Camp4 Therapeutics Corp (CAMP) director adds 16,378 shares in private deal
Rhea-AI Filing Summary
Camp4 Therapeutics Corp director Richard A. Young purchased 16,378 shares of common stock on August 3, 2026 at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement, increasing his direct holdings to 186,388 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 16,378 shares
Net Buy
1 txn
Insider
Young Richard A
Role
Director
Bought
16,378 shs ($27K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1 | 16,378 | $1.65 | $27K |
Holdings After Transaction:
Common Stock — 186,388 shares (Direct)
Footnotes (1)
- F1. On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.
Key Figures
Shares purchased: 16,378 shares
Purchase price: $1.65 per share
Total shares held after transaction: 186,388 shares
+1 more
4 metrics
Shares purchased
16,378 shares
Common stock acquired on August 3, 2026 in second closing of private placement
Purchase price
$1.65 per share
Price paid for each share in the August 3, 2026 acquisition
Total shares held after transaction
186,388 shares
Directly held Camp4 Therapeutics common stock after the reported purchase
Transaction date
August 3, 2026
Date of the private placement closing in which shares were acquired
Key Terms
private placement, Securities Purchase Agreement, institutional investors
3 terms
private placement financial
"acquired shares in the second closing of a private placement by the Issuer"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Securities Purchase Agreement financial
"pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
institutional investors financial
"by and among the Issuer and certain institutional investors and certain directors"
Institutional investors are large organizations, like pension funds, insurance companies, and mutual funds, that invest huge amounts of money on behalf of many people. Their decisions can influence the economy because they buy and sell big chunks of stocks, bonds, or other assets. They matter because their actions can affect market prices and trends.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Camp4 Therapeutics (CAMP) report for August 3, 2026?
Camp4 Therapeutics reported that director Richard A. Young purchased 16,378 shares of common stock on August 3, 2026. The shares were bought at $1.65 per share in the second closing of a private placement, increasing his overall ownership stake.
What is Richard A. Young’s role at Camp4 Therapeutics (CAMP) in this Form 4?
In this filing, Richard A. Young is identified as a director of Camp4 Therapeutics Corp and not as an officer. The reported acquisition therefore reflects a board member increasing a directly held position through participation in the company’s private placement.
Does this Camp4 Therapeutics (CAMP) Form 4 indicate use of a Rule 10b5-1 trading plan?
The document-level Rule 10b5-1 checkbox is not marked as an affirmative plan election. The transaction is instead described in relation to a Securities Purchase Agreement and a private placement closing, rather than being identified as executed under a pre-arranged trading plan.